Bronchodilator therapy in COPD: Current thinking and new paradigms
10 Nov 2017
Inhaled bronchodilator therapy is central to symptom management in chronic obstructive pulmonary disease (COPD), and evidence points to an improvement in lung function and a reduction in symptoms when dual bronchodilator therapy is used over monotherapy. Tiotropium/olodaterol (Spiolto® Respimat®, Boehringer Inghelheim) is the latest dual bronchodilator therapy available in Malaysia. At its launch during the Malaysian Thoracic Society Annual Congress 2017, Professor Klaus F. Rabe spoke on this particular combination and the evidence for its use in COPD.